Massimo Loda was named editor-in-chief of Molecular Cancer Research, published by the American Association for Cancer Research.Â
The Howard Hughes Medical Institute awarded research grants totaling at least $300 million to 33 researchers in biology and medicine from across the U.S.Â
A gift from financial services executive and entrepreneur Jim Belardi and his wife, Leslie, will support City of Hope’s research into the treatment of blood cancers, including leukemia, lymphoma, and multiple myeloma.
Alice Soragni of the UCLA Jonsson Comprehensive Cancer Center has received a $2.5 million grant from the NCI to develop lab-grown mini tumors that can help identify treatments for rare types of neuroendocrine cancer.Â
University of Minnesota researchers awarded NCI grant to study head and neck squamous cell carcinoma
A University of Minnesota research team was awarded an R01 grant for their project, which aims to develop a profile analysis of oral cell DNA that may predict head and neck squamous cell carcinoma susceptibility in smokers and assess the role of alcohol intake.
Thermo Fisher Scientific is accepting submissions for its Oncomine Clinical Research Grant.Â
A study identified racial and ethnic disparities in survival among newly diagnosed patients with childhood cancers in the U.S., with area-level socioeconomic status and health insurance contributing to these disparities.Â
Scientists at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute of The Ohio State University Comprehensive Cancer Center are studying tissues collected within hours of death to gather clues as to why certain cancers are able to spread and evolve.Â
Researchers at City of Hope showed that patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side effects when a multidisciplinary team of experts analyzed each case and introduced personalized interventions.Â
According to results from the PROpel phase III trial, Lynparza (olaparib) in combination with abiraterone had a significant positive effect on radiographic progression-free survival versus standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.
